Applied DNA Announces Availability And First Customer Shipment Of New Linea IVT Evaluation Kit
Portfolio Pulse from Happy Mohamed
Applied DNA Sciences, Inc. (NASDAQ:APDN) has announced the availability of its Linea IVT platform evaluation kits and the first shipment to an existing customer. The kit supports the conversion of current template evaluation customers to Linea IVT. The company expects a 3-fold increase in contract value compared to standalone orders of Linea IVT templates. The company plans to expand its base of evaluation customers ahead of bringing online its cGMP-quality production capacity in 2024.
August 29, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Applied DNA's announcement of the availability of its Linea IVT platform evaluation kits and the first shipment to an existing customer could potentially increase its revenues. The company's focus on expanding its customer base ahead of its 2024 production capacity launch could also positively impact its future earnings.
The availability of the new Linea IVT platform evaluation kits could attract more customers, potentially increasing Applied DNA's revenues. The company's strategy to expand its customer base ahead of its 2024 production capacity launch indicates a proactive approach to securing future earnings, which could positively impact its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100